To offer treatment to patients without current or recent sobriety and assess for sustained virologic response (SVR) rate after HCV treatment with elbasvir/grazoprevir
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 13 Jan 2022 New trial record
- 15 Nov 2021 Results presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases